HVTN 059

A Phase I, dose escalation, safety, and immunogenicity trial of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101) in healthy HIV-1 uninfected adult participants

Trial Details:

I Completed
AlphaVax, National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN) October 01, 2004
AVX101 Venezuelan Equine Encephalitis gag C
AVX101 Viral Vector - Alphavirus
Botswana, South Africa, USA 96